Technologie Servier, Orléans, France.
Eur J Pharm Sci. 2011 Dec 18;44(5):595-601. doi: 10.1016/j.ejps.2011.10.006. Epub 2011 Oct 13.
To overcome poor water-solubility of new drug candidates, four innovative surfactants based on naturally-occuring hydrophilic and hydrophobic moities were designed and synthesized: cholesteryl-glutamic acid, cholesteryl-poly[N-2-hydroxyethyl-l-glutamine] (PHEG), ursodeoxycholanyl-PHEG (UDCA-PHEG) and ursodeoxycholanyl-poly-l-glutamic acid (UDCA-PGA). Their self-assembling capacity was evaluated using pyrene fluorescence measurements which allow to determine their critical aggregation concentration (CAC). Size measurements were carried out using dynamic light scattering (DLS). Surfactant cytotoxicity was investigated on human umbilical vein endothelial cells (HUVEC) by determining tetrazolium salt (MTT) activity and lactate dehydrogenase (LDH) release. In addition, surfactant haemolytic activity was assessed using rat red blood cells (RBCs). Finally, the ability of these surfactants to solubilize a model poorly soluble drug was quantified. Surfactant self-assembly, cytotoxicity and solubilization properties were compared to those obtained with polysorbate 80, a model solubilizer. Except for cholesteryl-glutamic acid, surfactants were water-soluble. UDCA-PGA was not able to self-assemble or to increase significantly drug solubility. Results showed that cholesteryl-PHEG and UDCA-PHEG were self-assembling with low CAC values (17 and 120μg/ml) into nano-structures with mean diameters of 13 and 250nm, respectively. Cholesteryl-PHEG was the most efficient surfactant in increasing drug solubility (2mg/ml) but exhibited a similar or higher toxicity than polysorbate 80. UDCA-PHEG did not present any cytotoxicity but was far less efficient to solubilize the drug (0.2mg/ml). These results evidence interesting properties of cholesteryl-PHEG and UDCA-PHEG as novel solubilizers.
为了克服新候选药物的水溶性差的问题,设计并合成了四种基于天然亲水性和疏水性部分的创新表面活性剂:胆甾基-谷氨酸、胆甾基-聚[N-2-羟乙基-l-谷氨酸](PHEG)、熊去氧胆酸-PHEG(UDCA-PHEG)和熊去氧胆酸-聚-l-谷氨酸(UDCA-PGA)。使用芘荧光测量法评估了它们的自组装能力,该方法可以确定其临界聚集浓度(CAC)。使用动态光散射(DLS)进行了粒径测量。通过测定四唑盐(MTT)活性和乳酸脱氢酶(LDH)释放来研究表面活性剂对人脐静脉内皮细胞(HUVEC)的细胞毒性。此外,使用大鼠红细胞(RBC)评估了表面活性剂的溶血活性。最后,定量评估了这些表面活性剂溶解模型难溶性药物的能力。将表面活性剂的自组装、细胞毒性和增溶性质与模型增溶剂聚山梨酯 80 进行了比较。除胆甾基-谷氨酸外,所有表面活性剂均溶于水。UDCA-PGA 既不能自组装,也不能显著增加药物的溶解度。结果表明,胆甾基-PHEG 和 UDCA-PHEG 以低 CAC 值(17 和 120μg/ml)自组装成纳米结构,平均直径分别为 13nm 和 250nm。胆甾基-PHEG 是增加药物溶解度(2mg/ml)最有效的表面活性剂,但毒性与聚山梨酯 80 相似或更高。UDCA-PHEG 没有表现出任何细胞毒性,但对药物的增溶效率要低得多(0.2mg/ml)。这些结果证明了胆甾基-PHEG 和 UDCA-PHEG 作为新型增溶剂具有有趣的性质。